InMed Pharmaceuticals (NASDAQ: INM) completed its merger with privately held Mentari Therapeutics and changed its name to Mentari Therapeutics.
The combined company's shares are expected to begin trading on the Nasdaq Capital Market as MTRI on November 9, 2026. Immediately before closing, InMed completed its redomestication from British Columbia to Nevada, and pre-merger Mentari completed private financings totaling approximately $490 million in gross proceeds, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
Each pre-merger Mentari common share converted into the right to receive approximately 0.20065 combined-company shares, adjusted for the 1-for-10 reverse split effected November 4, 2026. InMed holders of record at the November 5, 2026 close received one non-transferable contingent value right per common share.
InMed Pharmaceuticals (NASDAQ: INM) expects its merger with Mentari Therapeutics to close on November 6, 2026, subject to remaining closing conditions. The company expects to redomesticate from British Columbia to Nevada before completion that day. Trading on the Nasdaq Capital Market under the name Mentari Therapeutics and symbol MTRI is expected to begin November 9, 2026.
A one-for-ten share consolidation became effective at Nasdaq market open on November 5, 2026. The company expects to issue one contingent value right, a right to conditional payments, per outstanding post-consolidation common share held by shareholders of record at the close of business that day. Payments depend on events and terms in the contingent value rights agreement. Shares issued for surrendered in-the-money stock options will not carry these rights.